A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects
of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a
Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
Phase:
Phase 1
Details
Lead Sponsor:
Novan, Inc.
Collaborator:
Spaulding Clinical Research LLC
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination